Neuro-Compass Toolbox

This App has been developed for healthcare professionals who care for people with multiple sclerosis (MS). Two tools are currently available: the Treatment Monitoring Tool and MS Progression Discussion Tool
Treatment Monitoring Tool
• Summarises the monitoring requirements recommended by the European Medicines Agency (EMA) for all disease modifying therapies (DMTs) approved for the treatment of people with MS in Europe.
• The App enables the user to view the monitoring requirements for up to four DMTs at the same time. The monitoring requirements are separated out into monitoring requirements before starting a patient on treatment, monitoring during treatment initiation and while treatment is ongoing, and monitoring requirements after stopping treatment with each disease modifying therapy.
MS Progression Discussion Tool (MSProDiscuss)
• The MS Progression Discussion Tool is a clinician-completed tool for use by healthcare professionals in clinical practice to educate and sensitize about the risk of progressing from RRMS to SPMS and facilitate physician-patient interaction.
• The tool uses information from patient symptoms and impacts experienced in the past 6 months to generate a traffic light system that complements physician discussion regarding patient progression to SPMS. It was developed based on qualitative research with clinicians and patients and empirical assessments of real-world evidence. It has been pilot-tested and validated with clinicians in the real world.
Neuro-Compass is an essential medical education resource, developed by a steering group of experts in MS with a breadth of knowledge and experience in the field.
This educational resource has been developed independently with educational funding from founding supporter Biogen International GmbH and further support from Novartis International AG. All content in the App is provided for informational purposes only. Please refer to the full prescribing information for your country when prescribing any disease modifying therapies.